InvestorsHub Logo
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

Re: OneDay4488 post# 34363

Saturday, 11/27/2021 9:59:13 PM

Saturday, November 27, 2021 9:59:13 PM

Post# of 42746

Looks like ALL shareholders should have done the same as Dale ?


Yep. I sold in August before the crash. It got to the point where the risk was greater than the reward. When the NIH changed the primary endpoint of the ACTIV-5, that was a sign that the EUA was not coming in the short term.

But the gamble is different now. HGEN might fall to $4 with a UK rejection. Then it will rebound to $5 or $6 because of CAR-T. Long term, HGEN is worth more than $6 per share just from CAR-T alone. It is probably worth $60 per share from CAR-T alone. But the Covid investors skew it in the short term.

HGEN will still look promising for a US FDA EUA after a UK rejection. Lenz is still the most efficacious Covid therapeutic according to the data. Maybe the UK will authorize, but it is still a good investment if they reject. I was worried in August so I sold. I am no longer worried now at $6.